Alnylam Pharmaceuticals Inc. (ALNY)

80.69
NASDAQ : Health Technology
Prev Close 78.37
Day Low/High 78.77 / 81.01
52 Wk Low/High 60.27 / 124.22
Avg Volume 718.60K
Exchange NASDAQ
Shares Outstanding 111.21M
Market Cap 8.72B
EPS -7.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
Alnylam To Host Second Annual Summer "RNAi Roundtable" Webcast Series

Alnylam To Host Second Annual Summer "RNAi Roundtable" Webcast Series

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it plans to host and webcast its annual summer series of online "RNAi Roundtables" this July, August, and...

Alnylam Pharmaceuticals (ALNY) Is Weak On High Volume Today

Alnylam Pharmaceuticals (ALNY) Is Weak On High Volume Today

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a weak on high relative volume candidate

Alnylam Reports New Positive Clinical Data For ALN-AT3, A Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Antithrombin (AT) For The Treatment Of Hemophilia And Rare Bleeding Disorders

Alnylam Reports New Positive Clinical Data For ALN-AT3, A Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Antithrombin (AT) For The Treatment Of Hemophilia And Rare Bleeding Disorders

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that new positive data from its ongoing Phase 1 clinical trial with ALN-AT3 - an investigational RNAi therapeutic for...

Alnylam Pharmaceuticals (ALNY) Weak On High Volume Today

Alnylam Pharmaceuticals (ALNY) Weak On High Volume Today

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a weak on high relative volume candidate

Alnylam Reports Positive Initial Clinical Results For ALN-CC5, An Investigational RNAi Therapeutic Targeting Complement Component C5 For The Treatment Of Complement-Mediated Diseases

Alnylam Reports Positive Initial Clinical Results For ALN-CC5, An Investigational RNAi Therapeutic Targeting Complement Component C5 For The Treatment Of Complement-Mediated Diseases

Alnylam Pharmaceuticals , Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, today announced initial positive results from its ongoing Phase 1/2 clinical trial with ALN-CC5, an investigational RNAi therapeutic...

Alnylam Files Trade Secret Misappropriation Suit Against Dicerna Pharmaceuticals

Alnylam Files Trade Secret Misappropriation Suit Against Dicerna Pharmaceuticals

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has filed a trade secret misappropriation lawsuit against Dicerna Pharmaceuticals, Inc.

Alnylam Appoints David-Alexandre Gros, M.D., Senior Vice President, Chief Business Officer

Alnylam Appoints David-Alexandre Gros, M.D., Senior Vice President, Chief Business Officer

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a leading RNAi therapeutics company, today announced the appointment of David-Alexandre "DA" Gros, M.

Alnylam To Present New Data At International Society On Thrombosis And Haemostasis (ISTH) 2015 Congress With ALN-AT3, An Investigational RNAi Therapeutic For The Treatment Of Hemophilia And Rare Bleeding Disorders (RBD)

Alnylam To Present New Data At International Society On Thrombosis And Haemostasis (ISTH) 2015 Congress With ALN-AT3, An Investigational RNAi Therapeutic For The Treatment Of Hemophilia And Rare Bleeding Disorders (RBD)

Alnylam Pharmaceuticals , Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it will present new interim Phase 1 clinical data and additional pre-clinical study results on ALN-AT3 - an...

Alnylam To Webcast Presentations At Upcoming June Investor Conferences

Alnylam To Webcast Presentations At Upcoming June Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the following conferences in June: Jefferies 2015...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ALNY, ATAI, DANG, ISSI, MTSI, TNP Downgrades: EMMS, EPIQ, IT, MSON, TFM Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

4 Big Biotech Companies to Sell Now

4 Big Biotech Companies to Sell Now

Biotech stocks are one of the hottest investment areas these days, but not all biotech stocks are smart buys.

Alnylam Initiates Phase 1 Clinical Trial For ALN-AS1, An Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase 1 (ALAS1) For The Treatment Of Acute Hepatic Porphyrias, Including Acute Intermittent Porphyria (AIP)

Alnylam Initiates Phase 1 Clinical Trial For ALN-AS1, An Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase 1 (ALAS1) For The Treatment Of Acute Hepatic Porphyrias, Including Acute Intermittent Porphyria (AIP)

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has initiated a Phase 1 clinical trial with ALN-AS1, a subcutaneously administered investigational RNAi...

Alnylam Receives Orphan Drug Designation From The United States Food & Drug Administration For Revusiran, An Investigational RNAi Therapeutic For The Treatment Of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

Alnylam Receives Orphan Drug Designation From The United States Food & Drug Administration For Revusiran, An Investigational RNAi Therapeutic For The Treatment Of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that the United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to revusiran, an...

Alnylam Files Clinical Trial Application (CTA) For ALN-AAT, An Investigational RNAi Therapeutic For The Treatment Of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease)

Alnylam Files Clinical Trial Application (CTA) For ALN-AAT, An Investigational RNAi Therapeutic For The Treatment Of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease)

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the U.

3 Health Care Stocks Nudging The Sector Higher

3 Health Care Stocks Nudging The Sector Higher

TheStreet highlights 3 stocks pushing the health care sector higher today.

Alynlam Pharmaceuticals (ALNY) Stock Falls in After-Hours Despite Better Than Expected Earnings

Alynlam Pharmaceuticals (ALNY) Stock Falls in After-Hours Despite Better Than Expected Earnings

Alynlam Pharmaceuticals (ALNY) shares declined despite earnings and revenue numbers that topped analysts' expectations.

Alnylam Pharmaceuticals Reports First Quarter 2015 Financial Results And Highlights Recent Period Progress

Alnylam Pharmaceuticals Reports First Quarter 2015 Financial Results And Highlights Recent Period Progress

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter 2015, and highlighted recent progress in advancing its pipeline.

Fear of a 'Soliris Killer' Might Have Driven Alexion to Overpay for Synageva

Fear of a 'Soliris Killer' Might Have Driven Alexion to Overpay for Synageva

Investors see Alexion's willingness to write a huge check for Synageva as a tacit acknowledgment that Soliris' long-term future might be more at risk than the company lets on.

Alnylam To Webcast Conference Call Discussing First Quarter 2015 Financial Results

Alnylam To Webcast Conference Call Discussing First Quarter 2015 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for the first quarter ending March 31, 2015 on Thursday, May 7, 2015, after the...

Alnylam To Webcast Presentations At Upcoming May Investor Conferences

Alnylam To Webcast Presentations At Upcoming May Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the following conferences in May: Deutsche Bank...

Alnylam Reports 12-Month Clinical Data From Phase 2 Open Label Extension (OLE) Study Of Patisiran, An Investigational RNAi Therapeutic For Patients With Familial Amyloidotic Polyneuropathy (FAP)

Alnylam Reports 12-Month Clinical Data From Phase 2 Open Label Extension (OLE) Study Of Patisiran, An Investigational RNAi Therapeutic For Patients With Familial Amyloidotic Polyneuropathy (FAP)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today initial 12-month clinical data from its ongoing Phase 2 open-label extension (OLE) study with patisiran, an...

New Lifetime High For Alnylam Pharmaceuticals (ALNY)

New Lifetime High For Alnylam Pharmaceuticals (ALNY)

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a new lifetime high candidate

Alnylam And Collaborators Publish Pre-clinical Study Results In Nature Medicine On ALN-AT3, An Investigational RNAi Therapeutic Targeting Antithrombin (AT) For The Treatment Of Hemophilia And Rare Bleeding Disorders (RBD)

Alnylam And Collaborators Publish Pre-clinical Study Results In Nature Medicine On ALN-AT3, An Investigational RNAi Therapeutic Targeting Antithrombin (AT) For The Treatment Of Hemophilia And Rare Bleeding Disorders (RBD)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the publication in Nature Medicine of pre-clinical results with ALN-AT3, an investigational RNAi therapeutic...

Alnylam To Webcast Presentation At 14th Annual Needham Healthcare Conference

Alnylam To Webcast Presentation At 14th Annual Needham Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 14 th Annual Needham Healthcare Conference on Wednesday, April...

Alnylam Pharmaceuticals (ALNY) Weak On High Volume

Alnylam Pharmaceuticals (ALNY) Weak On High Volume

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a weak on high relative volume candidate

Alnylam Presents Results From Natural History Study Of Patients With Familial Amyloidotic Cardiomyopathy (FAC) And Presents Complete Results From Phase 2 Clinical Trial For Revusiran, An Investigational RNAi Therapeutic For The Treatment Of FAC

Alnylam Presents Results From Natural History Study Of Patients With Familial Amyloidotic Cardiomyopathy (FAC) And Presents Complete Results From Phase 2 Clinical Trial For Revusiran, An Investigational RNAi Therapeutic For The Treatment Of FAC

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today results from a retrospective natural history study evaluating disease progression in transthyretin (TTR)-mediated...

Alnylam To Webcast Presentation At 22nd Annual Future Leaders In The Biotech Industry Conference

Alnylam To Webcast Presentation At 22nd Annual Future Leaders In The Biotech Industry Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 22 nd Annual Future Leaders in the Biotech Industry Conference...

Alnylam To Webcast Presentation At Barclays Global Healthcare Conference

Alnylam To Webcast Presentation At Barclays Global Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Barclays Global Healthcare Conference on Thursday, March 12, 2015...

Insiders Were Right: ALNY Makes New 52-Week High

Insiders Were Right: ALNY Makes New 52-Week High

In trading on Thursday, shares of Alnylam Pharmaceuticals Inc touched a new 52-week high of $115.43/share. That's a 145.44% rise, or $68.4 per share from the 52-week low of $47.03 set back on 04/28/2014.

Insider Trading Alert - ALNY, SCX And NSIT Traded By Insiders

Insider Trading Alert - ALNY, SCX And NSIT Traded By Insiders

Stocks with insider trader activity include ALNY, SCX and NSIT